ACP-105

{{Short description|Chemical compound}}

{{Drugbox

| IUPAC_name = 2-chloro-4-(3-hydroxy-3-methyl-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbenzonitrile

| image = ACP-105_structure.png

| tradename =

| legal_US = Investigational new drug

| legal_status =

| bioavailability =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number = 1048998-11-3

| PubChem = 11507567

| UNII =

| ChemSpiderID = 9682364

| ChEMBL = 3410856

| C=16 | H=19 | Cl=1 | N=2 | O=1

| SMILES = CC1=C(C=CC(=C1Cl)C#N)N2C3CCC2CC(C3)(C)O

| StdInChI= 1S/C16H19ClN2O/c1-10-14(6-3-11(9-18)15(10)17)19-12-4-5-13(19)8-16(2,20)7-12/h3,6,12-13,20H,4-5,7-8H2,1-2H3

| StdInChIKey = OUEODVPKPRQETQ-UHFFFAOYSA-N

}}

ACP-105 is a drug which acts as a selective androgen receptor modulator (SARM). It has been investigated for potential use in the treatment of age-related cognitive decline.{{cite journal | vauthors = Schlienger N, Lund BW, Pawlas J, Badalassi F, Bertozzi F, Lewinsky R, Fejzic A, Thygesen MB, Tabatabaei A, Bradley SR, Gardell LR, Piu F, Olsson R | display-authors = 6 | title = Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators | journal = Journal of Medicinal Chemistry | volume = 52 | issue = 22 | pages = 7186–7191 | date = November 2009 | pmid = 19856921 | doi = 10.1021/jm901149c }}{{cite journal | vauthors = Dayger C, Villasana L, Pfankuch T, Davis M, Raber J | title = Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in sham-irradiated and irradiated female mice | journal = Brain Research | volume = 1381 | pages = 134–140 | date = March 2011 | pmid = 21219889 | doi = 10.1016/j.brainres.2010.12.088 | pmc = 3048897 }}{{cite journal | vauthors = George S, Petit GH, Gouras GK, Brundin P, Olsson R | title = Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer's disease | journal = ACS Chemical Neuroscience | volume = 4 | issue = 12 | pages = 1537–1548 | date = December 2013 | pmid = 24020966 | doi = 10.1021/cn400133s | pmc = 3867967 }}{{cite journal | vauthors = Cutler C, Viljanto M, Taylor P, Hincks P, Biddle S, Van Eenoo P | title = Identification of equine in vitro metabolites of seven non-steroidal selective androgen receptor modulators for doping control purposes | journal = Drug Testing and Analysis | date = October 2021 | volume = 14 | issue = 2 | pages = 349–370 | pmid = 34714606 | doi = 10.1002/dta.3189 | s2cid = 240152623 | url = https://biblio.ugent.be/publication/8740373/file/8740375 | hdl = 1854/LU-8740373 | hdl-access = free }} The drug has been found to reduce anxiety-like behavior in a mouse model of Alzheimer's disease when administered alone, as well as enhance spatial memory when coadministered with the selective estrogen receptor β agonist AC-186. ACP-105 is an aniline SARM and is related to AC-262536 and vosilasarm (RAD140).{{cite journal | vauthors = Zhang X, Sui Z | title = Deciphering the selective androgen receptor modulators paradigm | journal = Expert Opinion on Drug Discovery | volume = 8 | issue = 2 | pages = 191–218 | date = February 2013 | pmid = 23231475 | doi = 10.1517/17460441.2013.741582 | s2cid = 2584722 }}